Completed PHASE1 INTERVENTIONAL 1-arm NCT01459016

A Non-drug Methods Study in Participants With Alzheimer's Disease

An Exploratory Study of Brain Imaging Biomarkers in Patients With Alzheimer's Pathology Receiving Standard of Care

Sponsor: Eli Lilly and Company

Interventions MRI Scan PET scan using florbetapir

Updated 8 times since 2017 Last updated: May 17, 2018 Started: Dec 31, 2011 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01459016, this PHASE1 trial focuses on Alzheimer's Disease and remains completed. Sponsored by Eli Lilly and Company, it has been updated 8 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jul 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Jul 2018 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Dec 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eli Lilly and Company

Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Cahors, France , Castres, France , Foix, France , Lavaur, France , Lille, France , Limoges, France , Léon, France , Marseille, France , Montauban, France , Nancy, France and 6 more locations